BioNIR Ridaforolimus Eluting Coronary Stent System (BioNIR) In Coronary Stenosis Trial

Trial Profile

BioNIR Ridaforolimus Eluting Coronary Stent System (BioNIR) In Coronary Stenosis Trial

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 17 Aug 2017

At a glance

  • Drugs Ridaforolimus (Primary) ; Zotarolimus
  • Indications Coronary artery disease
  • Focus Therapeutic Use
  • Acronyms BIONICS
  • Sponsors Medinol
  • Most Recent Events

    • 09 Aug 2017 Primary results of BIONICS study comparing safety and efficacy, published in the Circulation.
    • 21 Dec 2016 According to a Medinol media release, David Kandzari is the principal investigator for this study.
    • 21 Dec 2016 Primary endpoint (non-inferiority in coronary target lesion failure (a composite of cardiac death, target vessel myocardial infarction or ischemia-driven target lesion revascularization), at 12 months) has been met, as per a Medinol media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top